GlassScriptPhysician profile
Asek N Makia
NPI 1083615033
$11,295.53
in general payments reported to CMS, 2019-2025
26 companies · $3,045 in 2025
The $3,045 reported for 2025 was more than what 79% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $805 · 2021: $1,151 · 2022: $1,383 · 2023: $1,727 · 2024: $2,386 · 2025: $3,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,075 · Education: $82.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,075.22 |
| Education | $82.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,925.45 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $2,847.29 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,822.53 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $845.59 | 2021-2025 | Orladeyo |
| Pfizer INC. | $493.41 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $476.56 | 2019-2025 | Dupixent |
| Amgen INC. | $368.03 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $356.17 | 2023-2025 | |
| Optinose US, INC. | $208.41 | 2019-2025 | |
| Csl Behring | $123.84 | 2025 | Andembry, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $106.47 | 2023-2025 | Takhzyro |
| Aimmune Therapeutics, INC. | $93.55 | 2022 | |
| Genentech USA, INC. | $88.31 | 2024-2025 | Xolair |
| Viatris Specialty LLC | $86.50 | 2025 | Yupelri |
| Ionis Pharmaceuticals, INC. | $84.62 | 2025 | Dawnzera |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62.21 | 2022-2023 | |
| Mylan Specialty L.P. | $50.55 | 2024 | Yupelri |
| Galderma Laboratories, L.P. | $41.53 | 2025 | Nemluvio |
| Paratek Pharmaceuticals, INC. | $37.87 | 2025 | Xhance, Nuzyra |
| Alk-Abello, INC | $36.26 | 2019-2024 | Standardized Mite D. Farinae, Timothy, Standardized, Alternaria Tenuis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.49 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $33.71 | 2019-2021 | |
| Greer Laboratories, INC. | $19.38 | 2024 | Oralair |
| Phadia US INC. | $19.35 | 2019 | |
| Hikma Pharmaceuticals USA | $16.96 | 2022 | |
| Circassia INC. | $15.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asek Makia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.